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follow-up data in adult patients☆
Cystic fibrosis related liver disease (CFLD) contributes to
morbidity and mortality in cystic fibrosis (CF) [1]. Friedrich-Rust
et al. recently reported data of non-invasive ultrasound-based
methods for characterization of liver fibrosis in CF patients by
means of elastography [2]. The authors showed that both transient
elastography (TE) and acoustic radiation force impulse imaging
(ARFI) can serve as useful diagnostic tools for characterization of
CFLD associated liver fibrosis with high specificity. The results
are in line with previous studies in pediatric cohorts and with
our recently published data of 55 adult CF patients which show
that ARFI and TE can reliably detect CF-related liver cirrhosis
[3]. Friedrich-Rust et al. conclude that these methods may
add important clinical information to the recommended yearly
ultrasound follow-up of CFLD patients [1]. However, all studies
published so far are cross-sectional and longitudinal non-invasive
CFLD evaluation has not been reported yet.
We were able to prospectively characterize 41 of our 55
initially recruited adult CF patients [3] with liver elastography
after a median follow-up period of 22.5 months (male/female
n = 24/17; median age 33.5 years, range 22.0–55.9 years).
Nine individuals suffered from CFLD, among them six with
CF-induced liver cirrhosis. Of the 14 patients lost to elastography
follow-up, one died of cholangiocellular carcinoma, two died
of non-hepatic CF-related complications and one of unknown
cause. Among the remaining ten patients eight had a stable
clinical course (median follow-up 27.5 months), two were not
available for follow-up.
Within the 32 CF adults initially presenting without CFLD,
there was only one patient who potentially progressed to CFLD
with newly diagnosed hepatosplenomegaly and a TE and ARFI
increase from 4.9 to 6.7 kPa and 1.22 to 1.58 m/s, respectively,
after a follow-up period of 22 months. This patient was severely
malnourished and discontinued treatment with ursodeoxycholic
acid during follow-up. All patients with CFLD had a stable
clinical course since baseline. None of the cirrhotic individuals
suffered from hepatic decompensation such as bleeding compli-
cations or ascites.☆ Financial disclosure: TK received travel expenses from Echosens (Paris/France).
JW received lecturer fees from Siemens. All other authors have nothing to
disclose.
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rate at baseline b60%), while TE had a higher failure according
to the manufacturer's quality control criteria (n = 4 at baseline,
n = 3 at follow-up; n = 5 with a least one measurement failure).
At inclusion, the median liver stiffness measurement (LSM)
assessed by TE was 3.8 kPa (range 2.2–5.8 kPa) in patients
without CFLD and 5.3 kPa (range 3.0–19.9 kPa) in the CFLD
group. At follow-up, median LSM was 4.3 kPa (range 2.3–6.7)
in non-CFLD cases and 4.9 kPa (range 4.1–19.2 kPa) in CFLD
patients (Fig. 1a).
ARFI values showed comparable results: 1.11 m/s (non-CFLD,
range 0.94–1.36 m/s) and 1.27 m/s (CFLD, 0.97–2.12) at baseline
and 1.11 m/s (non-CFLD, range 0.73–1.66 m/s) and 1.60 m/s
(CFLD, range 1.01–2.12) at follow-up, respectively (Fig. 1b). TE
values differed significantly between patients with and without
CFLD at both time points (p b 0.05).
Intraclass correlation revealed a high accordance of TE
values and a significant correlation of ARFI results between the
two time points (intraclass correlation coefficients 0.91 and
0.74 for TE and ARFI, respectively). The median longitudinal
increase of LSM was +0.45 kPa (+9%) and +0.01 m/s (+1%)
for ARFI. 30 patients had fluctuations of more than 10% of
their baseline TE value at follow-up and 22 cases showed an
ARFI difference of more than 10% between the two time
points. However, most patients had LSM alterations below
our defined cut-off values (5.9 kPa for TE and 1.29 m/s for
ARFI, respectively) for CFLD detection [3]. Only three cases
showed a LSM increase above 5.9 kPa (maximum 7.6 kPa) at
follow-up (n = 1 with known CFLD, n = 1 without CFLD,
n = 1 malnourished patient discussed above). An increase of
ARFI N25% to N1.29 m/s was observed in three patients as
well (n = 2 with CFLD, n = 1 malnourished patient discussed
above).
In conclusion, our data provide first evidence that prospective
non-invasive assessment of liver stiffness is feasible in adult
CF-patients. Although potentially more accurate than ARFI, TE
has a failure rate which impairs longitudinal comparability in
N10% of cases. This disadvantage may be overcome by additional
follow-up examinations.
Our results underline the hypothesis of a stable course of
CFLD in the majority of adult CF patients once they have
passed adolescence [4]. However, the subtle increase of TE
values in selected patients may indicate slow progression of
liver disease which may become clinically relevant during a
longer follow-up period. The increase of TE results may
not only reflect progression of CFLD, but may also derive
from extrahepatic CF complications. The relevance of LSMby Elsevier B.V. All rights reserved.
Fig. 1. Elastography data from 41 patients with cystic fibrosis (median follow-up
period 22.5 months). Nine cases fulfilled the definition of cystic fibrosis related
liver disease (CFLD) at baseline examination.
827Letter to the Editorfluctuations within the range of normal values (e.g. increase
from 2.5 to 4.7 kPa in a patient who underwent lung transplan-
tation during follow-up) remains to be defined.
Whenever available, TE and ARFI shall be included in the
annual follow-up care for CF patients and should be further
evaluated in additional prospective studies with longer follow-up
periods. Pediatric patients may be the most interesting candidates
as these cohorts are at higher risk for CFLD development than
adult CF patients.
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